ADHD Therapeutics Market: What Will Be The Future Growth Opportunities?
SummaryGlobal ADHD Therapeutics Information, by drug types (Stimulants and Non-stimulants), by distribution channels (hospitals, clinics, pharmacies, research laboratories and others) - Forecast to 2024
- Author Company: Market Research Future
- Author Name: Reshu
- Author Email: firstname.lastname@example.org
- Author Telephone: +916468459312
Attention Deficit Hyperactivity Disorder (ADHD) Market Highlight
Attention Deficit Hyperactivity Disorder (ADHD), a neuro-developmental condition mostly occurs in childhood. However, if not appropriately treated in time, the disorder continues in adulthood as well. Patients, suffering from ADHD show symptoms of tenacious issues, such as impulsive behavior, difficulty in sustaining attention, and hyperactivity, etc. The exact cause leading to ADHD is still not known. However, prenatal tobacco exposure, premature birth, and genetics are some of the environmental factors considered as major risk factors for the occurrence of ADHD.
Request Free Sample @ https://www.marketresearchfuture.com/sample_request/1573
Similarly, though there is no breakthrough treatment available for ADHD till date, early detection and treatment can help patients to manage the conditions effectively. The global ADHD therapeutics market is growing pervasively over the past few years. Increasing prevalence of ADHD and advancements in the therapeutics to manage the conditions are key driving forces behind the growth of the market. Increase in the uses of medicines to treat ADHD presage towards the growth in the number of cases diagnosed and treated.
According to a leading research firm, Market Research Future (MRFR), the global ADHD therapeutics market is expected to perceive a phenomenal growth by 2024. In its recently published analysis, MRFR also asserts that the market would register a moderate CAGR throughout the forecast period (2017 – 2024). Additional factors that are substantiating the growth of the market include the burgeoning healthcare sector and the increasing number of advanced care providing facilities.
However, the number of patients receiving quality treatment worldwide is yet far little. In a few countries, ADHD is still under-diagnosed and remains untreated often. There are several options available for diagnosis and treatments of ADHD, ranging from behavioral intervention and prescription medication to digital medicines, which, positively impact the market growth. Spreading awareness among people about the condition and the availability of various therapeutics to treat the same is a key factor fostering the growth of the market. Additionally, antibiotics developed with advent technologies are providing preferable outcomes.
On the other hand, factors such as incidents of drug resistance, unmet clinical needs, and the high cost associated with the treatments are impeding the growth of the market. Nevertheless, the emergence of Biosimilars would support market growth, availing affordable medical products, and therapeutics.
ADHD Therapeutics Market - Geographical Analysis
North America leads the global ADHD therapeutics market with the largest market share. High healthcare expenditures and a large patient pool suffering from ADHD disorder are two key driving forces behind the growth of the regional market. The US, among other North American countries, leads the regional market creating a large revenue pocket. The region would retain its leading position in the global ADHD therapeutics market throughout the forecast period.
The European ADHD therapeutics market takes the second-leading position, heading with the significant technological advancements and the emergence of digital medicines. Moreover, the flourishing medical devices market and rising healthcare expenditure in the region are estimated to support the regional market growth.
The ADHD therapeutics market in the Asia Pacific region is emerging as a rapidly growing market, globally. Large patient population and unmet needs, alongside the availability of low-cost drugs for ADHD treatment, are key factors fostering the growth of the market. Besides, improving the economy in the region is acting as a key tailwind, pushing up the regional market and boosting the healthcare sector.
Furthermore, increasing funding support from the public and private organizations are substantiating the growth of the regional market. The proliferation of healthcare insurance mainly in countries, such as Malaysia, Thailand, and Vietnam is expected to drive the market growth in the APAC region. Also, the availability of new treatment methods that are increasingly meeting the growing demand for the ADHD therapeutics propels the regional market growth.
Global ADHD Therapeutics Market – Segments
The report is segmented into three market dynamics to widen the scope of understanding,
By Drug Type : Stimulants and Non-stimulants, among others.
By Distribution Channel : Hospitals, Clinics, Pharmacies, and Research Laboratories, among others.
By Regions : Europe, North America, Asia Pacific, and the Rest-of-the-World.
Global ADHD Therapeutics Market - Competitive Analysis
Highly competitive, the ADHD therapeutics market appears to be fragmented due to the presence of various well-established players. These players incorporate strategic approaches, such as mergers & acquisitions, collaboration, expansion, and product launch to maintain their positions in the market gaining a competitive advantage.
Highly competitive, the ADHD therapeutics market appears to be fragmented due to the presence of various well-established players. These players incorporate strategic approaches such as mergers & acquisitions, collaboration, expansion, and product launch to maintain their positions in the market, gaining a competitive advantage.
Players operating in the global ADHD therapeutics market, include Eli Lilly and Company, Concordia International Corp., Highland Therapeutics Inc., Novartis AG, Janssen Global Services LLC, NEOS Therapeutics Inc., Teva Pharmaceutical, Noven Pharmaceuticals Inc., Shire, and Pfizer Inc., among others.
May 15, 2019 ---- Auris Medical Holding Ltd. (Switzerland), a pharmaceutical company announced the closing of two US patent acquisitions related to the use of betahistine for the treatment of depression and ADHD. Auris Medical is a clinical-stage company dedicated to developing therapeutics to address major unmet medical needs in neurotology and central nervous system disorders. The Company acquired full ownership of the US patents 8,242,148 and 8,119,668 for its novel medicine betahistine, effective in the treatment of depression and ADHD.
To view the full report, visit at https://www.marketresearchfuture.com/reports/adhd-therapeutics-market-1573
Table Of Content
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
Latest Trending Report In Healthcare
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312